Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State

•82 % of respondents whose main drug was an opioid wanted to reduce their opioid use.•46 % of respondents whose main drug was methamphetamine wanted to reduce their use.•Concern about anxiety and depression was associated with interest in reducing use.•Resources to reduce substance use should be off...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug and alcohol dependence 2020-11, Vol.216, p.108243-108243, Article 108243
Hauptverfasser: McMahan, Vanessa M, Kingston, Susan, Newman, Alison, Stekler, Joanne D., Glick, Sara N., Banta-Green, Caleb J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•82 % of respondents whose main drug was an opioid wanted to reduce their opioid use.•46 % of respondents whose main drug was methamphetamine wanted to reduce their use.•Concern about anxiety and depression was associated with interest in reducing use.•Resources to reduce substance use should be offered at SSPs, jails, and clinics.•Many supports were endorsed, including medications for drug use and mental health. Methamphetamine use is increasing, and opioid use remains elevated in the US. Understanding interest in reducing/stopping substance use among people who inject drugs (PWID), as well as types of help wanted, can inform interventions. Data from the 2019 Washington State Syringe Exchange Survey were used in logistic regression analyses to assess if demographics, substance use, and concern about anxiety or depression were associated with interest in reducing/stopping substance use among people whose main drug was methamphetamine or opioids. Types of help wanted to reduce/stop use are reported. Of 583 participants included, 76 % reported opioids were their main drug, of whom 82 % were interested in reducing/stopping their opioid use. 24 % reported methamphetamine as their main drug, of whom 46 % were interested in reducing/stopping their methamphetamine use. Among those whose main drug was an opioid, female gender (AOR:2.19, p = .023) and concern about depression (AOR:3.04, p = .002) were associated with interest in reducing/stopping opioid use. Among participants whose main drug was methamphetamine, being in jail in the past year and having an infection likely related to injection (e.g., abscess) in the past year were associated with over twice the odds of interest in reducing/stopping methamphetamine use (AOR:2.14, p = .056 and 2.43, p = .052, respectively); however, these findings were not significant. Several types of help to reduce/stop use were endorsed. There were high, though differing, levels of interest in reducing/stopping opioid or methamphetamine use and in a range of support services. PWID should be asked about interest in reducing/stopping use and provided appropriate support.
ISSN:0376-8716
1879-0046
1879-0046
DOI:10.1016/j.drugalcdep.2020.108243